BeOne Medicines (NASDAQ:ONC – Free Report) had its price target upped by Wells Fargo & Company from $400.00 to $435.00 in a report published on Friday,Benzinga reports. The firm currently has an overweight rating on the stock.
Several other brokerages have also recently issued reports on ONC. Morgan Stanley reissued an “overweight” rating and issued a $425.00 price objective on shares of BeOne Medicines in a research note on Friday, October 16th. TD Cowen lifted their target price on shares of BeOne Medicines from $424.00 to $454.00 and gave the company a “buy” rating in a report on Thursday, August 6th. JPMorgan Chase & Co. lifted their target price on shares of BeOne Medicines from $425.00 to $445.00 and gave the company an “overweight” rating in a report on Thursday, October 1st. Weiss Ratings upgraded shares of BeOne Medicines from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, October 8th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $470.00 price target on shares of BeOne Medicines in a report on Thursday. Sixteen equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $434.79.
Get Our Latest Analysis on BeOne Medicines
BeOne Medicines Stock Up 5.1%
NASDAQ ONC traded up $19.71 during trading hours on Friday, hitting $406.96. 941,725 shares of the company were exchanged, compared to its average volume of 364,122. BeOne Medicines has a 52-week low of $253.95 and a 52-week high of $410.71. The company has a 50 day moving average of $363.49 and a two-hundred day moving average of $326.34. The company has a quick ratio of 3.06, a current ratio of 3.40 and a debt-to-equity ratio of 0.17. The firm has a market cap of $44.68 billion, a price-to-earnings ratio of 51.71 and a beta of 0.63.
BeOne Medicines (NASDAQ:ONC – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported $3.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.34 by $1.30. The firm had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.76 billion. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%. Equities research analysts anticipate that BeOne Medicines will post 8.99 earnings per share for the current year.
Insider Buying and Selling
In other BeOne Medicines news, CEO John Oyler sold 54,892 shares of the business’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $358.15, for a total transaction of $19,659,569.80. Following the sale, the chief executive officer directly owned 240,743 shares in the company, valued at approximately $86,222,105.45. The trade was a 18.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Xiaodong Wang sold 31,028 shares of the business’s stock in a transaction on Tuesday, October 27th. The stock was sold at an average price of $362.97, for a total transaction of $11,262,233.16. Following the sale, the insider owned 31,028 shares in the company, valued at $11,262,233.16. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 376,373 shares of company stock valued at $134,848,154 in the last quarter. Corporate insiders own 6.19% of the company’s stock.
Institutional Trading of BeOne Medicines
A number of institutional investors have recently added to or reduced their stakes in the stock. Mather Group LLC. grew its position in BeOne Medicines by 192.0% during the third quarter. Mather Group LLC. now owns 73 shares of the company’s stock worth $27,000 after buying an additional 48 shares during the period. GAMMA Investing LLC lifted its position in shares of BeOne Medicines by 39.5% during the 3rd quarter. GAMMA Investing LLC now owns 120 shares of the company’s stock valued at $44,000 after acquiring an additional 34 shares during the period. Parallel Advisors LLC boosted its stake in shares of BeOne Medicines by 24.0% during the 1st quarter. Parallel Advisors LLC now owns 351 shares of the company’s stock worth $104,000 after acquiring an additional 68 shares in the last quarter. Provenance Wealth Advisors LLC purchased a new stake in shares of BeOne Medicines during the 3rd quarter worth approximately $106,000. Finally, Knights of Columbus Asset Advisors LLC acquired a new stake in shares of BeOne Medicines in the 3rd quarter worth approximately $106,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.
Key BeOne Medicines News
Here are the key news stories impacting BeOne Medicines this week:
- Positive Sentiment: BeOne reported Q3 EPS of $3.64, above the $2.34 consensus, and revenue of $1.89 billion, topping estimates of $1.76 billion. The company also raised its 2026 revenue guidance, supporting a stronger outlook. Q3 earnings and guidance
- Positive Sentiment: The FDA granted priority review to a BRUKINSA combination for first-line mantle cell lymphoma. A faster review could bring a potential label expansion sooner, though approval is not guaranteed. FDA priority review
- Positive Sentiment: Several firms raised price targets while maintaining bullish ratings: RBC to $465, Citizens JMP to $463, Truist to $448, Barclays to $446, and Wells Fargo to $435. The revisions signal continued analyst confidence in BeOne’s prospects. RBC rating information Citizens JMP rating information Truist rating information Barclays rating information Wells Fargo rating information
BeOne Medicines Company Profile
BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia.
Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.
Recommended Stories
- Five stocks we like better than BeOne Medicines
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
